By Chris Wack

 

Codex DNA Inc. said it entered a strategic collaboration and licensing agreement with Pfizer Inc. to access and further develop Codex DNA's novel EDS technology for potential application by Pfizer for its mRNA-based vaccines and other biopharma products.

The company said the financial terms of the deal include an upfront payment from Pfizer to Codex DNA, along with success-based technical milestone payments that could be earned in the near term.

Codex DNA also is eligible to receive additional milestone payments based on the achievement of specified development, regulatory and commercialization goals associated with any products developed from the application of Codex DNA's technology developed and licensed under the agreement.

Under this agreement, Pfizer gains early access to custom, state-of-the-art Codex DNA technology, including use of its proprietary short oligo ligation assembly SOLA EDS technology.

Codex DNA said it will continue to offer its catalog of synthetic genomes, including SARS-CoV-2, for research use for discovering monoclonal antibody treatments, small-molecule therapies, diagnostic assays, and new vaccines against specific variants.

Codex DNA shares were up 26% to $11.85 in premarket trading.

 

Write to Chris Wack at chris.wack@wsj.com

 

(END) Dow Jones Newswires

January 10, 2022 07:22 ET (12:22 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
過去 株価チャート
から 4 2022 まで 5 2022 Pfizerのチャートをもっと見るにはこちらをクリック
Pfizer (NYSE:PFE)
過去 株価チャート
から 5 2021 まで 5 2022 Pfizerのチャートをもっと見るにはこちらをクリック